ContraFect (NASDAQ:CFRX) reported quarterly losses of $(0.46) per share. This is a 228.57 percent decrease over losses of $(0.14) per share from the same period last year.
EXCLUSIVE: HeartSciences Announces Expansion of Artificial Intelligence Patent Portfolio
Heart Test Laboratories Inc d/b/a HeartSciences (NASDAQ: HSCS) has been issued a notice of patent allowance from the European Patent Office.